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Early M-Protein Dynamics Predicts Progression-Free 
Survival in Patients With Relapsed/Refractory Multiple 
Myeloma
Xiaoyu Yan1,*,†, Xu Steven Xu2 ,*,†, Katja C. Weisel3,4, Maria-Victoria Mateos5, Pieter Sonneveld6, Meletios A. Dimopoulos7,  
Saad Zafar Usmani8, Nizar J. Bahlis9, Thomas Puchalski10, Jon Ukropec10, Kevin Bellew10, Qi Ming10, Steven Sun2  
and Honghui Zhou10
This study aimed to predict long-term progression-free survival (PFS) using early M-protein dynamic measurements in pa-
tients with relapsed/refractory multiple myeloma (MM). The PFS was modeled based on dynamic M-protein data from two 
phase III studies, POLLUX and CASTOR, which included 569 and 498 patients with relapsed/refractory MM, respectively. Both 
studies compared active controls (lenalidomide and dexamethasone, and bortezomib and dexamethasone, respectively) alone 
vs. in combination with daratumumab. Three M-protein dynamic features from the longitudinal M-protein data were evaluated 
up to different time cutoffs (1, 2, 3, and 6 months). The abilities of early M-protein dynamic measurements to predict the PFS 
were evaluated using Cox proportional hazards survival models. Both univariate and multivariable analyses suggest that maxi-
mum reduction of M-protein (i.e., depth of response) was the most predictive of PFS. Despite the statistical significance, the 
baseline covariates provided very limited predictive value regarding the treatment effect of daratumumab. However, M-protein 
dynamic features obtained within the first 2 months reasonably predicted PFS and the associated treatment effect of dara-
tumumab. Specifically, the areas under the time-varying receiver operating characteristic curves for the model with the first 
2 months of M-protein dynamic data were ~ 0.8 and 0.85 for POLLUX and CASTOR, respectively. Early M-protein data within the 
first 2 months can provide a prospective and reasonable prediction of future long-term clinical benefit for patients with MM.
Daratumumab is a human immunoglobulin G (IgGκ) mono-
clonal antibody that targets CD38 and kills malignant 
plasma cells via direct antitumor and immunomodulatory 
mechanisms of action.1–7 Daratumumab induces anti-
tumor activity through several CD38 immune-mediated 
actions, including complement-dependent cytotoxicity, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  M-protein is a biomarker for tumor burden and its levels 
in the serum and urine have been used to assess treat-
ment responses for patients with multiple myeloma (MM).
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Whether early M-protein data in the first several months 
can provide a prospective prediction for long-term benefit 
and treatment effect.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
✔  By using clinical data collected from two pivotal phase 
III trials of daratumumab in relapsed or refractory MM, 
we demonstrated that M-protein dynamic data collected 
during the first 2  months of therapy can provide a pro-
spective and reasonable prediction for not only long-term 
progression-free survival (PFS) but also the treatment ef-
fects of daratumumab on PFS compared with other active 
controls.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  Early M-protein dynamic data within the first 2 months 
of therapy may enable the designers of clinical trials to 
predict the probability of treatment success, and thus fa-
cilitate decision making in developing new drugs for MM.
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antibody-dependent cellular cytotoxicity, antibody-depen-
dent cellular phagocytosis, apoptosis, and modulation of 
CD38 enzymatic activity.1–5 Daratumumab also induces an 
immunomodulatory effect by minimizing the immune-sup-
pressive functions of CD38+ myeloid-derived suppressor 
cells, regulatory T cells, and regulatory B cells, and increas-
ing T-cell clonality.6
In the phase III clinical studies POLLUX (MMY3003) and 
CASTOR (MMY3004), daratumumab in combination with 
standards of care regimens lenalidomide and dexameth-
asone (Rd), and bortezomib and dexamethasone (Vd), 
respectively, reduced the risk of disease progression or death 
by ≥ 50%, doubled the rates of complete response or better, 
and more than tripled the rates of minimal residual disease 
negativity based on next-generation sequencing at the 10–5 
sensitivity threshold vs. standard of care alone in patients 
with relapsed/refractory multiple myeloma (MM).8–11 These 
findings led to the approval of daratumumab (16 mg/kg) in 
combination with Rd, and Vd in patients with relapsed and 
refractory MM in many countries worldwide. Daratumumab 
has also been approved as monotherapy in many countries 
and in combination with pomalidomide and dexamethasone 
in the United States.
In MM, tumor plasma cell produces a large amount of 
monoclonal IgG or IgG free light chain (FLC), known as 
M-protein. M-protein is a biomarker for tumor burden and 
its levels in the serum and urine have been used to assess 
treatment responses for patients with MM.12 Dispenzieri 
et al.13 demonstrated the utility of FLC after 2 months of 
therapy to predict the overall response. Furthermore, 
several other studies have shown retrospective associa-
tion between FLC/M-protein reduction and the long-term 
benefit, such as progression-free survival (PFS) or overall 
survival,13–18 which is critical for predicting antitumor activ-
ities for new agents and personalizing therapy for patients 
with myeloma.
To date, the retrospective studies of the association be-
tween M-protein dynamics and PFS or overall survival have 
been mainly based on complete M-protein dynamic data col-
lected up to the time of disease progression.13–18 Therefore, 
the prospective ability of M-protein, particularly early mea-
surements within 2–3 months of therapy, to predict long-term 
survivals remains unknown. Moreover, because most of 
existing association studies were performed based on non-
randomized, single-arm phase II studies,13–15,17,19 translation 
of the significant association between M-protein and survival 
in these studies to treatment effects compared with control 
arms in the randomized phase III studies is still challenging. 
Furthermore, existing association studies have mainly focused 
on reduction in the M-protein level at a static single time point 
(e.g., end of 8 weeks) without considering dynamic informa-
tion or features of M-protein (e.g., variation in M-protein levels 
over time, and rate of M-protein changes).13,14,18
Here, we investigated the usefulness of early M-protein 
dynamic data collected during the first several months after 
treatment initiation as a predictor of PFS and the effects of 
treatment on PFS. This analysis is based on the clinical data of 
two, large-scale phase III studies, POLLUX and CASTOR for 
daratumumab. We evaluated different features of M-protein 
dynamics in addition to M-protein reduction and compared 
the predictive performance of M-protein dynamic data within 
different periods after treatment. With this analysis, we hy-
pothesized that an early interim analysis based on M-protein 
dynamics within a couple of months after treatment could 
prospectively predict the future long-term treatment effect 
on PFS. Such predictions would contribute greatly to pre-
dictions of the probability of success of future clinical trials, 
decision making in drug development, and the prevision of 
individualized guidance for treatment and patient care.
METHODS
Study design and data collection
POLLUX (ClinicalTrials.gov identifier, NCT02076009) and 
CASTOR (ClinicalTrials.gov identifier, NCT02136134) were 
phase III, multicenter, randomized (1:1), active-controlled 
studies evaluating the efficacy and safety of daratumumab 
plus active control vs. active control alone in patients with 
relapsed and refractory MM. In POLLUX, 569 patients were 
randomly assigned to the daratumumab group (n  =  286) 
or control group (n  =  283). Daratumumab 16  mg/kg was 
administered once weekly for 8  weeks (cycles 1–2), fol-
lowed by every 2  weeks for 16  weeks (cycles 3–6), and 
then every 4 weeks thereafter.8 Both groups received lena-
lidomide and dexamethasone throughout the treatment 
period. Combination of daratumumab with lenalidomide 
and dexamethasone were compared with lenalidomide 
and dexamethasone (Rd) alone in patients with relapsed 
or refractory MM. In CASTOR, 498 patients were randomly 
assigned to the daratumumab group (n  =  251) or control 
group (n = 247). Patients in the former group received dara-
tumumab 16 mg/kg once weekly for 9 weeks (cycles 1–3), 
followed by every 3 weeks for 15 weeks (cycles 4–8), and 
every 4 weeks thereafter.9 In contrast to POLLUX, all patients 
in CASTOR only received up to eight cycles (3 weeks per 
cycle) of bortezomib and dexamethasone. Daratumumab 
plus bortezomib and dexamethasone were compared with 
bortezomib and dexamethasone (Vd) alone in patients with 
relapsed and refractory disease treated with a median of 
two lines of therapy. Table S1 presented a comparison of 
POLLUX and CASTOR in terms of study design.
For POLLUX, M-protein measurements were collected 
at screening, and on day 1 of each treatment cycle for 
18  months. Subsequently, M-protein measurements were 
collected every two cycles until the end of treatment. 
For CASTOR, M-protein measurements were collected 
at screening, then day 1 of each treatment cycle for the 
first eight cycles. After cycle 8 (i.e., beginning of cycle 9), 
M-protein measurements were collected every cycle for the 
first 18 months of the study and every other month thereaf-
ter until the end of the treatment.
The clinical data cutoff dates were March 7, 2016, for 
POLLUX and January 11, 2016, for CASTOR.8,9 The data-
set of POLLUX and CASTOR contain 169 and 189 events 
of disease progression or death, respectively. Details of the 
study designs have been described previously.8,9 Both stud-
ies were approved by the institutional review boards of the 
participating institutions and were conducted in accordance 
with the ethical principles of the World Medical Association 
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Statistical analysis
Cox proportional hazards (PHs) analyses were performed 
on PFS using the survival package in R 3.5.3.20 M-protein 
dynamic data from each patient were extracted. For each 
patient, if serum M-protein was measurable, dynamic data 
for serum M-protein was used. However, if serum M-protein 
was not measurable, whereas urine M-protein was measur-
able, dynamic data for urine M-protein was used. Finally, if 
both serum and urine M-protein were unmeasurable, serum 
FLC data were used. Because the units of M-protein are 
different among different measurements, the M-protein 
dynamic data were normalized as the observed percent 
change of M-protein from the baseline vs. time curve as 
shown in Figure S1. The normalization is based on the fol-
lowing equation:
where MPt represents the M-protein measurements over 
time, and MP0 represents the baseline M-protein measure-
ments. Three M-protein dynamic features were extracted, 
namely the maximum percent reduction (representing max-
imal tumor reduction), last observed percent change of 
M-protein (representing tumor burden change at the last 
observation), and rate of M-protein change (representing 
the rate of tumor progression; i.e., the slope of the regres-
sion line connecting the measurements between the last 
and previous observations, as illustrated in Figure S1). To 
study the predictive ability of early M-protein dynamics, we 
extracted three dynamic features within different time cutoffs 
for M-protein measurements (1, 2, 3, and 6 months as well 
as complete M-protein data up to the clinical cutoff dates). 
That is, a set of dynamic features was extracted for each 
cutoff of the M-protein data, without changing the number 
of patients in the datasets. Univariate Cox analysis was con-
ducted for individual M-protein features. In the subsequent 
multivariable analysis, a stepwise screening was conducted 
to identify the most significant baseline covariates using 
Bayesian information criterion. The three M-protein dynamic 
features at different time cutoffs were then added to the 
model without further variable selection. Predictive abilities 
of three dynamic features were assessed in this multivari-
able setting. Furthermore, the areas under the curve (AUC) 
corresponding to the time-varying receiver operating charac-
teristic (ROC) curve of the different models were calculated 
and compared to evaluate the predictive performance of the 
final Cox PH model.21 The models were then validated fur-
ther using external cross-validation methods; specifically, the 
models constructed based on POLLUX data were used to 
predict PFS from the CASTOR data and vice versa. A land-
mark analysis was also conducted at different time points 
corresponding to the M-protein cutoff dates.22
We explored whether predictions based on dynamic 
M-protein data would be superior to those based on static 
M-protein data. The M-protein measurements at static time 
points (i.e., 1 and 2 months) were used to construct models 
that were then compared with the models based on dynamic 
features. The AUCs of the ROC curves based on these mod-
els were calculated and compared.
M-protein dynamic modeling
Longitudinal M-protein dynamic modeling was performed 
using a tumor growth inhibition (TGI) model to evaluate the 
treatment effect of daratumumab.23–25 The details of this 
model are described in the Supplementary Materials.
RESULTS
Treatment effect of daratumumab as demonstrated by 
univariate analysis and M-protein dynamic modeling
Univariate analysis showed a strong treatment effect of 
daratumumab. In the univariate Cox analysis provided in 
Tables S2 and S3, all M-protein dynamic features were 
significantly associated with PFS (P < 0.0001) except for 
the rate of M-protein change within the first month, indi-
cating that M-protein dynamics are highly correlated with 
PFS. Figure 1 presents a comparison of the mean values 
of (with 95% confidence interval) of M-protein dynamic 
features observed in the daratumumab and control arm of 
both POLLUX and CASTOR studies. This comparison re-
vealed an apparent difference in these features between 
daratumumab and control groups. Specifically, for all the 
investigated time cutoffs, the last observation and max-
imum reduction in the daratumumab-treated group were 
significantly lower than that of the control group, thus 
demonstrating a strong treatment effect of daratumumab 
and potential predictive abilities of these two M-protein 
dynamic features. However, the difference in the rate of 
change in M-protein between the two groups was less 
apparent.
We also evaluate the treatment effect of daratumumab 
using a TGI model for M-protein dynamics. The model 
diagnostic plots of the TGI modeling are provided in the 
Figure S2, which showed that the TGI model adequately 
describes the M-protein dynamics data from the POLLUX 
and CASTOR studies. The parameter estimates are pro-
vided in Table S4. The precisions of parameter estimates 
are expressed as relative standard error and are all within 
30%. Interestingly, the estimated treatment effect of da-
ratumumab in the combination therapy compared with 
standard of cares are 0.546 for POLLUX and 0.526 for 
CASTOR, indicating an increase of over 50% in the tumor 
decay rate induced by daratumumab. The model-based 
simulation in Figure 2 showed daratumumab combina-
tion therapies in CASTOR and POLLUX provided a greater 
reduction in M-protein and more persistent inhibition of 
tumor growth compared with the active control arm (Rd in 
CASTOR and Vd in POLLUX).
Association between PFS and M-protein dynamic 
features after adjusting for baseline variables as 
demonstrated by multivariable analysis
Figure 3 shows the statistical significance of all covariates 
included in the model using the M-protein up to 1 month, 
2 months, and the last observation (i.e., all data). Slope of 
M-protein change was only significant in PULLUX using 
M-protein data collected up to 1  month. Except for the 
1 month data cutoff in PULLUX, the maximum reduction of 
M-protein was significant in both studies for different data 
cutoffs. The last observation of M-protein was significant 
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data) in POLLUX, and when using 2 months cutoff and all 
data in CASTOR.
Tables 1 and 2 present the hazard ratio for each covariate 
included in the final multivariable Cox PH models for POLLUX 
and CASTOR, along with the M-protein dynamic features 
derived from the data up to different time cutoffs. When 
only 1 month of M-protein data were included, it was very 
challenging to obtain reasonable estimates of the effect of 
M-protein dynamics on PFS (Tables 1 and 2). This is demon-
strated by that the estimates of hazard ratios associated with 
the selected dynamic features using 1 month data differed 
markedly from those obtained from all data (Tables 1 and 2). 
However, with inclusion of 2 months or more M-protein data, 
it appears that the effect of M-protein could be much better 
estimated. Consistent from the results shown in Figure 3, all 
three M-protein features barely showed any statistical sig-
nificance with only 1 month of data. The M-protein dynamic 
features (maximum reduction or/and last observed value) 
started to show significance once 2  months of data were 
included, and become highly significant when all data were 
used to construct the models (Figure 3).
Based on the analysis with M-protein data up to the last 
observation (i.e., all data), time from MM diagnosis to ran-
domization was significantly associated with PFS for both 
studies (Figure 3), suggesting that patients who survived a 
longer time tend to have better PFS. Furthermore, based on 
analysis of all the data in POLLUX (Table 1 and Figure 3), 
the cytogenetic risk, history of treatment with thalidomide or 
proteasome inhibitors, and higher bone marrow plasma cell 
levels were associated with a shorter PFS, whereas a higher 
baseline hemoglobin level was significantly associated 
with a longer PFS (e.g., lower risk). Moreover, patients with 
IgG type of M-protein tend to have better PFS. Consistent 
with the POLLUX data, our previously reported findings 
also suggested that compared with patients with non-IgG 
MM, patients with IgG MM appear to be more sensitive to 
daratumumab treatment.26 However, this result might be 
confounded with the baseline level of disease severity, as 
the non-IgG group included a larger portion of patients with 
International Staging System stage III (24.4%) relative to 
the IgG group (16.6%). Based on the analysis of all data in 
CASTOR (Table 2 and Figure 3), a higher number of lytic 
bone lesions, higher IgG concentration, elevated alkaline 
phosphatase levels, history of lenalidomide therapy, higher 
number of previous lines of therapy lines, and International 
Staging System stage (II or III), were significantly associated 
with a higher risk of progression or death, suggesting that 
more severe disease might lead to a shorter PFS.
M-protein dynamics as early as the first 2 months can 
provide reasonable predictions for PFS and treatment 
effect
We further overlaid the Cox-PH prediction based on the mul-
tivariable model with observed survival curve to evaluate 
Figure 1 Observed means and 95% confidence intervals of the dynamic features of baseline-normalized M-protein data up to different 
time cutoffs from the POLLUX and CASTOR studies.
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whether M-protein dynamic features are predictive of the 
long-term benefit of treatment effect for patients with MM 
(Figure 4). Despite the statistical significance, the base-
line covariates have very limited predictive value in terms 
of the treatment effect as there was no separation of the 
predicted PFS for the daratumumab arm and active control 
arm in POLLUX. For CASTOR, there is a slight separation 
for the predicted PFS curves. This is not surprising as for 
each study, patients in the daratumumab arm should have 
similar baseline characteristics compared with those in the 
control arm due to randomization. However, the predicted 
PFS for daratumumab and control arms started to show 
separation when the M-protein dynamic features from the 
first month of M-protein data were included in the mod-
els. With the addition of further M-protein data from the 
first 2 months, a reasonable prediction of treatment effect 
on PFS can be observed for both CASTOR and POLLUX. 
Boxplots of AUCs from the time-varying ROC curves of 
each model (Figure 5) confirmed that, with the inclusion 
of M-protein dynamic features from the first 2 months of 
data, the AUC increased to > 0.7 for POLLUX and > 0.8 for 
CASTOR. For POLLUX, the model continued to improve 
with the inclusion of more M-protein data (Figure 5). For 
CASTOR, the performance of the model using M-protein 
data obtained within the first 2 months was almost equal 
to that of the model that included all available M-protein 
data (Figure 5). Moreover, our sensitivity landmark analy-
sis demonstrated that the predictive performance for both 
CASTOR and POLLUX models was robust after account-
ing for the lead bias (Figures S3 and S4).
To evaluate whether the dynamic M-protein data can pro-
vide a better prediction for PFS compared with the static 
M-protein data at fixed time points, boxplots comparing the 
AUC values of time-varying ROC curves from different ap-
proaches are presented in Figure S5. For both the POLLUX 
and CASTOR studies, the AUCs of the ROC curves based on 
dynamic M-protein data were consistently higher than those 
based on static M-protein data. Interestingly, for CASTOR, 
the static M-protein measurement at the end of 1  month 
provided better predictions than the static measurement at 
the end of 2 months, indicating the inconsistency of static 
M-protein data for PFS prediction. These results highlight 
the superiority of dynamic data compared with static mea-
surements to predict long-term benefit.
Cross (external) validation further confirmed the predic-
tive capacity of early M-protein dynamics (Figure S6). The 
model based on early M-protein dynamics (first 2 months) 
from POLLUX yielded a similar prediction of the treatment 
effect on PFS for the CASTOR data compared with that 
using the original CASTOR model. Similarly, the CASTOR 
model provided an adequate prediction for the treatment ef-
fect on PFS for POLLUX data.
DISCUSSION
The change in tumor size has been demonstrated to cor-
relate with the survival for various cancers, including 
non-small cell lung cancer,27 colon cancer,28 breast can-
cer,29 and MM.13–15 However, most previous correlative 
analyses were based either on complete dynamic data col-
lected during the studies or on the tumor size at specific 
static time points (e.g., 8 weeks). Therefore, these analyses 
generally provided information only regarding the retro-
spective association between long-term survival and the 
full tumor profile or partial static data. Early dynamic mea-
surements may help to predict the impact of drug activity 
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on survival and guide early decision making or treatment 
individualization. Unfortunately, to date, very little research 
has been performed to evaluate the predictive performance 
of early dynamic measurements in terms of long-term sur-
vival benefits.
In this paper, we compared the predictive ability of 
M-protein dynamic features based on data collected up 
to 1, 2, 3, and 6  months, and all available data following 
daratumumab administration using clinical data collected 
from POLLUX and CASTOR (sample size 569 and 498, re-
spectively). We demonstrated that M-protein dynamic data 
collected during the first 2 months of therapy can provide a 
prospective and reasonable prediction for not only long-term 
PFS but also the treatment effects of daratumumab on PFS 
compared with other active controls. Although M-protein 
has different subclasses, such as IgA, IgD, IgE, IgG, IgM, 
and FLC, the IgG M-protein has the longest half-life (about 
20  days on average).30 Therefore, active agents would be 
expected to exert sizeable treatment effects on M-protein 
dynamics in the majority of patients after 2 months (60 days, 
3 half-lives) of treatment.
The analysis showed that the reduction of M-protein is 
the most important predictor for PFS. This is consistent with 
previous studies for other cancers where the tumor shrink-
age is a significant predictor for survival.15,29 Furthermore, 
we demonstrated the superiority of dynamic data for pre-
dicting PFS compared with static measurements at fixed 
time points. Given the heterogeneous nature of MM,31 the 
M-protein dynamic data are more informative than static 
measurements collected at a specific time point.
We also investigated the predictive performance of two 
other M-protein dynamic features, namely last observation 
Figure 3 Statistical significance (-log10P) of each variable in a multivariable analysis from the (a) POLLUX and (b) CASTOR studies. 
The vertical dashed line indicates a P value of 0.05. Maximum reduction = maximum M-protein reduction (% change from baseline); 
Last observation = last M-protein observation (% change from baseline); slope = rate of M-protein change (%/week). ECOG, Eastern 
Cooperative Oncology Group; IgG, interleukin G; ISS, International Staging System; MM, multiple myeloma; PI, prior lenalidomide.
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Table 1 Multivariable analysis of M-protein dynamic features and identified baseline variables for PFS in the POLLUX (n = 569) study
Variable, unit
HRs (95% CIs) based on M-protein data up to the indicated time cutoffs








- 10.2 (1.94–54) 1.1 (0.86–1.41) 1.01 (0.705–1.44) 1.23 (0.831–1.82) 0.903 (0.63–1.29)
Rate of M-protein 
change, % per 
week
- 1.5 (0.899–2.51) 1.02 (0.921–1.14) 1.07 (0.986–1.16) 1.01 (0.984–1.03) 1.03 (1.01–1.05)




1.1 (1.04–1.16) 0.947 (0.9–0.997) 0.936 (0.888–0.986) 0.943 (0.896–0.993) 0.947 (0.9–0.997) 0.945 (0.897–0.997)
Cytogenetic risk 
high vs. standard
1.92 (1.30–2.83) 1.96 (1.33–2.89) 1.77 (1.19–2.64) 1.76 (1.17–2.65) 1.77 (1.18–2.66) 1.72 (1.15–2.58)
Prior thalidomide 
yes vs. no
1.45(1.06–1.98) 1.38 (0.993–1.91) 1.28 (0.926–1.76) 1.14 (0.83–1.58) 1.22 (0.886–1.68) 1.22 (0.883–1.68)
Prior PI yes vs. no 1.78 (1.07–2.96) 1.76 (1.05–2.94) 1.57 (0.942–2.61) 1.43 (0.86–2.38) 1.37 (0.82–2.27) 1.37 (0.82–2.28)
Type of myeloma 
IgG vs. non-IgG
0.565 (0.415–0.77) 0.55 (0.402–0.751) 0.489 (0.356–0.672) 0.506 (0.367–0.698) 0.51 (0.371–0.701) 0.493 (0.358–0.679)
Hemoglobin, g/L 0.808 (0.736– 0.887) 0.789 (0.717–0.868) 0.807 (0.732–0.89) 0.802 (0.728–0.884) 0.803 (0.73–0.884) 0.814 (0.74–0.896)
Bone marrow 
plasma cells, %
0.94 (0.892–0.991) 1.12 (1.05–1.18) 1.12 (1.06–1.19) 1.12 (1.06–1.19) 1.11 (1.05–1.18) 1.12 (1.05–1.18)
For hemoglobin (g/L), bone marrow plasma cells (%), maximum reduction of M-protein (%), and last observed M-protein change from baseline (%), the hazard 
ratio is associated with each 10-unit increase.
Table 2 Multivariable analysis of M-protein dynamic features and identified baseline variables for PFS in the CASTOR (n = 498) study
Variable
HRs (95% CIs) based on M-protein data up to the indicated time cutoffs








- 0.838 (0.63–1.11) 1.08 (1.04–1.12) 1.11 (1.08–1.15) 1.02 (1.01–1.04) 1.02 (1.01–1.04)
Rate of M-protein 
change, % per 
week
- 1.09 (0.92–1.28) 0.987 (0.927–1.05) 0.934 (0.874–0.999) 0.998 (0.945–1.05) 0.996 (0.943–1.05)
Time from MM 
diagnosis to 
randomized, years
0.819 (0.764–0.879) 0.839 (0.785–0.897) 0.868 (0.813–0.926) 0.873 (0.817–0.932) 0.857 (0.801–0.917) 0.855 (0.799–0.915)
Number of lytic bone 
lesions
1.3 (1.16–1.47) 1.83 (1.22–2.77) 2 (1.31–3.05) 1.87 (1.23–2.85) 1.8 (1.18–2.74) 1.82 (1.2–2.77)
IgG concentration, 
g/dL
1.01 (1.01–1.02) 1.01 (1–1.02) 1.01 (1–1.02) 1.01 (1–1.02) 1.01 (1–1.02) 1.01 (1–1.02)
Alkaline 
phosphatase, IU/L
1.01 (1–1.01) 1.04 (1.02–1.08) 1.04 (1.02–1.08) 1.04 (1.01–1.07) 1.04 (1.01–1.07) 1.04 (1.01–1.07)
Prior lenalidomide 
yes vs. no
2.260 (1.62–1.47) 1.65 (1.16–2.33) 1.62 (1.15–2.29) 1.5 (1.05–2.12) 1.55 (1.1–2.18) 1.47 (1.04–2.07)
Number of prior 
therapy lines
1.880 (1.25–2.82) 1.24 (1.09–1.42) 1.18 (1.04–1.35) 1.18 (1.04–1.35) 1.2 (1.06–1.37) 1.21 (1.06–1.37)
ISS, II or III vs. I 1.600 (1.14–2.40) 1.36 (0.971–1.92) 1.43 (1.02–2) 1.26 (0.893–1.77) 1.63 (1.15–2.3) 1.62 (1.15–2.3)
Prior radiotherapy 
yes vs. no
1.510 (1.09–2.1) 1.25 (0.9–1.74) 1.29 (0.921–1.8) 1.13 (0.802–1.58) 1.3 (0.929–1.83) 1.28 (0.914–1.8)
ECOG score, 1 or 2 
vs. 0
0.950 (0.697–1.29) 0.954 (0.704–1.29) 0.985 (0.726–1.34) 1.1 (0.81–1.5) 0.927 (0.679–1.27) 0.923 (0.676–1.26)
For maximum reduction of M-protein (%) and last observed M-protein change from baseline (%), the hazard ratio is associated with each 10-unit increase.
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of M-protein within certain time windows and slope of 
change in M-protein trajectory. The simple univariate anal-
ysis indicated that all features were important, supporting 
the importance of M-protein dynamics for prediction of 
long-term PFS. However, multivariable analysis results re-
vealed that the maximum reduction appears to be the most 
statistically significant predictors for PFS, confirming that 
the depth of response is the most important predictor for 
the long-term benefit.32 In contrast, the last observation of 
M-protein was a statistically significant predictor only for the 
CASTOR dataset. In POLLUX, the continuous deepening of 
the M-protein response during the first year of therapy might 
have led to minimum differentiation between maximum re-
duction and last observation, and, thus, confounded these 
two dynamic features. In CASTOR, however, the M-protein 
levels, particularly in the control arm, appeared to progress 
Figure 4 Comparison of the predicted probability of progression-free survival based on the final multivariable survival models, with 
the observed probability over time (Kaplan–Meier survival curves) in the POLLUX (n = 569) and CASTOR (n = 498) studies. For POLLUX 
and CASTOR, the hazard ratio for progression-free survival was in favor of daratumumab treated group with P < 0.001.8,9 The predict 
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Figure 5 AUCs under the time-varying ROC curves from the multivariable survival models based on M-protein data from the POLLUX 
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a few months after the initiation of the therapy (Figure 2), 
and differentiated between the maximum reduction and last 
observation (Figure 2). Accordingly, both features provided 
useful information for PFS prediction in the CASTOR study. 
Regarding the slope, this factor was no longer a significant 
predictor in the multivariable analysis after adjusting for the 
reduction and the last observation of M-protein, indicating 
that the other two features completely explained its informa-
tion. In CASTOR, the background treatment of bortezomib 
and dexamethasone were only administered up to eight cy-
cles (~ 4 months). The beginning of progress of M-protein 
at 4 months in the control arm is reflective of this cessation 
of treatment. In contrast, the M-protein response in the da-
ratumumab arm demonstrates the continued benefit of the 
experimental treatment.
The survival prediction based on M-protein dynamic fea-
tures differed slightly between POLLUX and CASTOR. The 
predictive ability of M-protein dynamics in terms of PFS of 
patients in POLLUX continuously improve with more longi-
tudinal M-protein data, whereas the prediction performance 
of the M-protein data from CASTOR started to plateau after 
2 months (Figure 5). This observation is consistent with the 
clinical responses to daratumumab observed in these two 
studies. In POLLUX, the median time to complete remis-
sion or better was 13.2  months in the daratumumab arm, 
indicating a continuous deepening of response over the first 
year of treatment. In CASTOR, the corresponding time was 
4.21 months, suggesting a much more rapid onset of maxi-
mum drug effect. It is well known that deep response in MM 
is associated with long-term survival benefit.32 Therefore, 
due to the rapid onset of maximum drug effect in CASTOR, 
it is not surprising that the maximum predictive performance 
can be attained with early M-protein dynamic measurements 
within 2 months of therapy in this study. In POLLUX, however, 
2 months of data could also yield a reasonable prediction of 
the treatment effect (i.e., separation of the PFS curves), al-
though the addition of further dynamic data yielded slightly 
better prediction. The deepening of response over the long 
time observed in POLLUX is consistent with the observation 
that under Rd, the response can continue to deepen after 
years.33 Therefore, the lack of a rapid very good partial re-
sponse to lenalidomide-based therapy should not discourage 
treatment continuation to a deeper response or encourage 
a too-early switch in treatment. Nevertheless, the M-protein 
dynamic data clearly shows that unlike other diseases where 
combination therapy may trigger more resistance,34 combi-
nation therapies containing daratumumab could significantly 
slow down disease progression in patients with MM.
Our analysis had some limitations of note. First, although the 
M-protein dynamics could provide a reasonable prediction of 
the treatment effect on PFS, it still tended to underpredict the 
treatment effect as the predicted separation in PFS curves 
was slightly smaller than the observed separation (Figure 4). 
To further improve the prediction, a more sensitive biomarker 
than M-protein is required. Recent research suggested that 
minimal residual disease, which is measured using flow cy-
tometry, multiparameter flow cytometry, polymerase chain 
reaction, next-generation sequencing, and positron emission 
tomography/computed tomography methods, may be used 
as a surrogate biomarker to evaluate the efficacy.32 Future 
research is warranted to evaluate the predictive capability of 
minimal residual disease dynamics, particularly early mea-
surements, for survival outcomes. Second, this analysis was 
conducted using clinical data from two phase III studies of 
daratumumab in patients with relapsed and refractory MM. 
The generalizability of the model was not externally validated 
with data involving other agents. Clinical data from studies 
of other agents would be helpful to further confirm our find-
ings. Nevertheless, strong associations between M-protein 
and clinical outcomes (based on complete data across entire 
study duration) have been reported in multiple publications 
and for different treatments.14,15,19,35,36 In addition, the percent 
reduction of M-protein has been used to define international 
response criteria for MM, which has been widely used in 
clinical trials.12 Therefore, our findings in the current study 
regarding the good predict ability of early M-protein dynam-
ics is very likely generalizable. Third, as the objective of the 
present research was to provide a practical modeling tool for 
clinical researchers and scientists to predict long-term clin-
ical efficacy endpoints (e.g., PFS) and associated treatment 
effect using early (e.g., first 2 months) M-protein dynamics, 
we did not investigate the disease biology, particularly mech-
anism of drug resistance, using the M-protein data. Recently, 
Tang et al. constructed sophisticated biological models using 
M-protein dynamics data from three randomized controlled 
trials of bortezomib, and showed that bortezomib-based 
therapy exerts a selection pressure on the tumor cells, lead-
ing to interpatient variability.37 Future research using Tang et 
al.’s approach may be warranted to explore if daratumumab 
has a similar effect on myeloma cells.
In conclusion, our analyses based on the clinical data 
from POLLUX (n  =  569) and CASTOR (n  =  498) demon-
strated that early M-protein dynamic features obtained from 
data within the first 2  months following treatment could 
provide prospective and reasonable predictions of future 
long-term clinical benefits in patients with MM. The models 
developed in this paper allow prediction of the probability of 
success for clinical trials to facilitate the decision making in 
drug development (e.g., early predictions of phase III clinical 
study outcomes at early interim analyses or when only early 
phase I/II data are available). Early M-protein dynamic read-
outs may also enable individualized guidance for treatment 
and patient care.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
Acknowledgments. The authors thank the patients participating 
in this study and their families, as well as the global network of investiga-
tors, research nurses, study coordinators, and operations staff.
Funding. This work was supported by the start-up grant from School 
of Pharmacy, The Chinese University of Hong Kong.
Conflict of Interest. X.S.X., T.P., J.U., K.B., Q.M., S.S., and H.Z. 
are employees of Janssen Research & Development, LLC. X.S.X., T.P., 
J.U., K.B., Q.M., S.S., and H.Z. own stock in Johnson & Johnson. K.W. 
reports research funding from Janssen, Amgen, Sanofi, and Celgene 
Corporation; honoraria from Amgen, Bristol-Myers Squibb, Celgene 
10
Clinical and Translational Science
Early M-Protein Dynamics and Multiple Myeloma
Yan et al.
Corporation, Janssen, Novartis, Onyx, and Takeda; and advisory board 
membership for Adaptive Biotech, Amgen, Bristol-Myers Squibb, 
Celgene Corporation, Janssen, Novartis, Onyx, and Takeda. M.V.M. re-
ceived honoraria from and consulted for Janssen, Celgene, Takeda, and 
Amgen. A.S. received research funding and personal fees from Janssen 
Cilag. P.S. reports research funding from Janssen, Celgene, Amgen, 
and Takeda; received honoraria from Janssen, Celgene, Amgen, and 
Takeda; and provided expert testimony for Pharma Mar. M.A.D. con-
sulted for Amgen, Janssen-Cilag, and Takeda; received travel expenses 
from Janssen-Ortho and Genesis Pharmaceuticals; received honoraria 
from Amgen, Novartis, Celgene, Takeda, Genesis Pharmaceuticals, 
Janssen-Cilag, and Bristol-Myers Squibb; and received research 
funding from Janssen-Cilag and Amgen. S.Z.U. consulted for Abbvie, 
GlaxoSmithKline, Celgene, Amgen/Onyx, Takeda/Millennium, Sanofi, 
Seattle Genetics, Skyline, Merck, and Janssen; received research fund-
ing from Celgene, Amgen/Onyx, Takeda/Millennium, Sanofi, Seattle 
Genetics, Skyline, Merck, Janssen, Array BioPharma, and Pharmacyclics; 
served on speakers bureaus for Celgene, Amgen, Janssen, Sanofi, and 
Takeda; and received travel expenses from Janssen, Celgene, Amgen, 
and Takeda. N.J.B. received honoraria and travel expenses from 
Celgene, Takeda, Janssen, and Amgen; served on advisory boards for 
Celgene, Takeda, Janssen, and Amgen; served on speaker’s bureaus for 
Celgene, Janssen, and Amgen; and received research funding from and 
provided expert testimony to Celgene and Janssen. All other authors 
declared no competing interests for this work.
Author Contributions. X.Y., X.S.X., K.C.W., M.V.M., P.S., M.A.D., 
S.Z.U., N.J.B., T.P., J.U., K.B., Q.M., S.S., and H.Z. wrote the manuscript. 
X.Y., X.S.X., K.C.W., M.V.M., P.S., M.A.D., S.Z.U., N.J.B., N.J.B., T.P., J.U., 
K.B., Q.M., S.S., and H.Z. designed the research. X.Y., X.S.X., K.C.W., 
M.V.M., P.S., M.A.D., S.Z.U., N.J.B., N.J.B., T.P., J.U., K.B., Q.M., S.S., and 
H.Z. performed the research. X.Y. and X.S.X analyzed the data.
 1. de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal 
antibody, induces killing of multiple myeloma and other hematological tumors. J. 
Immunol. 186, 1840–1848 (2011).
 2. Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor 
activity of the therapeutic antibody daratumumab in lymphoma and multiple my-
eloma. MAbs. 7, 311–321 (2015).
 3. Overdijk, M. B. et al. The therapeutic CD38 monoclonal antibody daratumumab 
induces programmed cell death via Fcgamma receptor-mediated cross-linking. J. 
Immunol. 197, 807–813 (2016).
 4. Lammerts van Bueren, J. et al. Direct in vitro comparison of daratumumab with 
surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 
124, 3474 (2014).
 5. van de Donk, N. W. C. J. et al. Monoclonal antibodies targeting CD38 in hematolog-
ical malignancies and beyond. Immunol. Rev. 270, 95–112 (2016).
 6. Krejcik, J. et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes 
T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 
384–394 (2016).
 7. DARZALEX™®(daratumumab) injection [packet insert]. (Janssen Biotech, Inc, 
Horsham, PA, 2019).
 8. Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple my-
eloma. N. Engl. J. Med. 375, 754–766 (2016).
 9. Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for mul-
tiple myeloma. N. Engl. J. Med. 375, 1319–1331 (2016).
 10. Mateos, M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for 
untreated myeloma. N. Engl. J. Med. 378, 518–528 (2018).
 11. Spencer, A. et al. Daratumumab plus bortezomib and dexamethasone versus bor-
tezomib and dexamethasone in relapsed or refractory multiple myeloma: updated 
analysis of CASTOR. Haematologica 103, 2079–2087 (2018).
 12. Durie, B. G. et al. International uniform response criteria for multiple myeloma. 
Leukemia 20, 1467–1473 (2006).
 13. Dispenzieri, A. et al. Appraisal of immunoglobulin free light chain as a marker of 
response. Blood 111, 4908–4915 (2008).
 14. Dytfeld, D. et al. Superior overall survival of patients with myeloma achieving very 
good partial response or better to initial treatment with bortezomib, pegylated 
liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free 
light chain- and M-protein-based model: extended follow-up of a phase II trial. 
Leuk. Lymphoma. 52, 1271–1280 (2011).
 15. Vij, R. et al. Serum free light chain reduction correlates with response and pro-
gression-free survival following carfilzomib therapy in relapsed/refractory multiple 
myeloma. Leuk. Lymphoma 56, 2959–2961 (2015).
 16. Shimizu, K. et al. Posttreatment M-protein nadir level is a significant prognostic 
factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative 
Study Group. Jpn. J. Cancer Res. 90, 355–360 (1999).
 17. Oivanen, T. M. Prognostic value of serum M-protein doubling time at escape from 
plateau of multiple myeloma. The Finnish Leukaemia Group. Eur. J. Haematol. 57, 
247–253 (1996).
 18. Shah, J. et al. Rapid early monoclonal protein reduction after therapy with bortezomib 
or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is 
associated with a longer time to progression. Cancer 117, 3758–3762 (2011).
 19. Michallet, M. et al. Heavy+light chain monitoring correlates with clinical outcome in 
multiple myeloma patients. Leukemia 32, 376–382 (2018).
 20. R Core Team. R: A Language and Environment for Statistical Computing (R 
Foundation for Statistical Computing, Vienna, Austria, 2018).
 21. Blanche, P., Dartigues, J.F. & Jacqmin-Gadda, H. Estimating and comparing 
time-dependent areas under receiver operating characteristic curves for censored 
event times with competing risks. Stat Med. 32, 5381–5397 (2013).
 22. Dafni, U. Landmark analysis at the 25-year landmark point. Circ. Cardiovasc. Qual. 
Outcomes 4, 363–371 (2011).
 23. Jonsson, F. et al. A tumor growth inhibition model based on M-protein levels in sub-
jects with relapsed/refractory multiple myeloma following single-agent carfilzomib 
use. CPT Pharmacometrics Syst. Pharmacol. 4, 711–719 (2015).
 24. Ribba, B. et al. A review of mixed-effects models of tumor growth and effects of 
anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst. 
Pharmacol. 3, e113 (2014).
 25. Xu, X.S. et al. Correlation between prostate-specific antigen kinetics and overall 
survival in abiraterone acetate-treated castration-resistant prostate cancer pa-
tients. Clin. Cancer Res. 21, 3170–3177 (2015).
 26. Yan, X. et al. Influence of disease and patient characteristics on daratumumab 
exposure and clinical outcomes in relapsed or refractory multiple myeloma. Clin. 
Pharmacokinet. 57, 529–538 (2018).
 27. Claret, L. et al. A model of overall survival predicts treatment outcomes with 
atezolizumab versus chemotherapy in non-small cell lung cancer based on early 
tumor kinetics. Clin. Cancer Res. 24, 3292–3298 (2018).
 28. Claret, L. et al. Evaluation of tumor-size response metrics to predict overall survival 
in Western and Chinese patients with first-line metastatic colorectal cancer. J. Clin. 
Oncol. 31, 2110–2114 (2013).
 29. Wang, Y. et al. Elucidation of relationship between tumor size and survival in non-
small-cell lung cancer patients can aid early decision making in clinical drug devel-
opment. Clin. Pharmacol. Ther. 86, 167–174 (2009).
 30. Lobo, E.D., Hansen, R.J. & Balthasar, J.P. Antibody pharmacokinetics and pharma-
codynamics. J. Pharm. Sci. 93, 2645–2668 (2004).
 31. Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implica-
tions. Nat. Rev. Clin. Oncol. 14, 100–113 (2017).
 32. Paiva, B., van Dongen, J.J. & Orfao, A. New criteria for response assessment: role 
of minimal residual disease in multiple myeloma. Blood 125, 3059–3068 (2015).
 33. Facon, T. et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-
front treatment for multiple myeloma. Blood 131, 301–310 (2018).
 34. Leary, M., Heerboth, S., Lapinska, K. & Sarkar, S. Sensitization of drug resistant 
cancer cells: a matter of combination therapy. Cancers (Basel) 10, 483 (2018).
 35. Harutyunyan, N.M. et al. Levels of uninvolved immunoglobulins predict clinical sta-
tus and progression-free survival for multiple myeloma patients. Br. J. Haematol. 
174, 81–87 (2016).
 36. Schaefer, E.W. et al. Residual serum monoclonal protein predicts progression-free 
survival in patients with previously untreated multiple myeloma. Cancer 116, 640–
646 (2010).
 37. Tang, M. et al. Myeloma cell dynamics in response to treatment supports a model of 
hierarchical differentiation and clonal evolution. Clin. Cancer Res. 22, 4206–4214 
(2016).
© 2020 The Authors. Clinical and Translational Science 
published by Wiley Periodicals LLC on behalf of the 
American Society for Clinical Pharmacology and 
Therapeutics. This is an open access article under 
the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use 
and distribution in any medium, provided the original 
work is properly cited, the use is non-commercial and 
no modifications or adaptations are made.
